
About this episode
Professor Elias Dakwar at Columbia University has conducted research studies – supported by federal funding -- into the use of ketamine combined with mindfulness meditation to help people struggling with addiction and depression. I wanted to understand everything about this: Why is he among the very few researchers to receive funding from the National Institute on Drug Abuse for this sort of work? How does ketamine compare to psilocybin and other psychedelics? What is the experience of subjects in his studies? How does his approach to administering ketamine compare to others? What’s the added benefit of including mindfulness mediation? And what does he think about the future of psychedelic studies and his role in this burgeoning field?
Listen to this episode and let me know what you think. Our number is 1-833-779-2460. Our email is [email protected]. Or tweet at me, @ethannadelmann.
Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time PSYCHOACTIVE publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from PSYCHOACTIVE

Steve Rolles on Legalizing Drugs
PSYCHOACTIVE

Charley & Shelley Wininger On Healthy Aging & Sex with MDMA
PSYCHOACTIVE

Paul Gootenberg on the Global History of Drugs
PSYCHOACTIVE

Dennis McKenna on The Brotherhood of the Screaming Abyss
PSYCHOACTIVE